Avalo Therapeutics, Inc.
$927.80M- Market cap
- $1.03B
- Debt
- +-$5.17M
- Cash
- −$98.34M
Capital structure 101% equity / -1% debt · EV / Revenue 15725.35x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · View financials
Decision snapshot: AVTX stock price vs ATGE: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ATGE's multiple
Needs ATGE P/S.
Implied fair value · at AVTX's multiple
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AVTX FY 2025 (ended Dec 31, 2025) · ATGE FY 2026 (ended Jun 30, 2026). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 101% equity / -1% debt · EV / Revenue 15725.35x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AVALO THERAPEUTICS, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Covista Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-0.06x
0.46x
Net debt / EBITDA
Leverage against operating earnings
1.33x
0.54x
Cash and equivalents
Liquid reserves on the balance sheet
$98.34M
$406.32M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
CytomX Therapeutics, Inc.
AVTX vs CTMX
IDEAYA Biosciences, Inc.
AVTX vs IDYA
Ocugen, Inc.
AVTX vs OCGN
CLOVER HEALTH INVESTMENTS, CORP. /DE
AVTX vs CLOV
Citius Pharmaceuticals, Inc.
AVTX vs CTXR
CHEGG, INC
AVTX vs CHGG
AMERICAN PUBLIC EDUCATION INC
AVTX vs APEI
Grand Canyon Education, Inc.
AVTX vs LOPE
Stride, Inc.
AVTX vs LRN
UNIVERSAL TECHNICAL INSTITUTE INC
AVTX vs UTI
Strategic Education, Inc.
AVTX vs STRA
-$5.17M
$667.95M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.